Versant Venture Capital VI, L.P.'s Form 4 filing
Monte Rosa Therapeutics, Inc. (GLUE) · filed Sep 13, 2024
- Accession no.
- 0000950170-24-106532
- Filed
- Sep 13, 2024, 6:44 PM ET
- Trade date
- Sep 11-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Vantage I, L.P.CIK 0001765253 | 10% Owner |
| Versant Vantage I GP, L.P.CIK 0001777651 | 10% Owner |
| Versant Ventures VI GP-GP, LLCCIK 0001777652 | 10% Owner |
| Versant Vantage I GP-GP, LLCCIK 0001777653 | 10% Owner |
| Versant Ventures VI GP, L.P.CIK 0001777654 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2024 | Common Stock | SSaleDisposed | −541,897 | $6.00 | −$3,251,382 | 6,257,218 | Direct | |
| Sep 12, 2024 | Common Stock | SSaleDisposed | −16,047 | $6.00 | −$96,309.28 | 6,241,171 | Direct | |
| Sep 13, 2024 | Common Stock | SSaleDisposed | −9,269 | $6.16 | −$57,099.82 | 6,231,902 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.